BioVie Inc (NASDAQ: BIVI)’s stock price has gone decline by -14.29 in comparison to its previous close of 0.98, however, the company has experienced a -25.00% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-03-27 that CARSON CITY, Nev., March 27, 2025 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a virtual investor event featuring key opinion leader (KOL) Lindsay McAlpine, MD, BSc (Yale University), who will join company management to discuss the unmet need and current treatment landscape for long COVID on Thursday, April 10, 2025 at 10:00 AM ET. To register, click here.
Is It Worth Investing in BioVie Inc (NASDAQ: BIVI) Right Now?
BIVI has 36-month beta value of 1.27. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BIVI is 16.04M, and currently, short sellers hold a 7.80% ratio of that float. The average trading volume of BIVI on April 02, 2025 was 582.36K shares.
BIVI’s Market Performance
BIVI stock saw a decrease of -25.00% in the past week, with a monthly decline of -28.81% and a quarterly a decrease of -60.56%. The volatility ratio for the week is 10.44%, and the volatility levels for the last 30 days are 8.84% for BioVie Inc (BIVI). The simple moving average for the past 20 days is -22.19% for BIVI’s stock, with a -66.75% simple moving average for the past 200 days.
Analysts’ Opinion of BIVI
Many brokerage firms have already submitted their reports for BIVI stocks, with Cantor Fitzgerald repeating the rating for BIVI by listing it as a “Overweight.” The predicted price for BIVI in the upcoming period, according to Cantor Fitzgerald is $7 based on the research report published on July 22, 2022 of the previous year 2022.
B. Riley Securities, on the other hand, stated in their research note that they expect to see BIVI reach a price target of $47. The rating they have provided for BIVI stocks is “Buy” according to the report published on January 15th, 2021.
BIVI Trading at -41.88% from the 50-Day Moving Average
After a stumble in the market that brought BIVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.80% of loss for the given period.
Volatility was left at 8.84%, however, over the last 30 days, the volatility rate increased by 10.44%, as shares sank -29.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -62.50% lower at present.
During the last 5 trading sessions, BIVI fell by -25.00%, which changed the moving average for the period of 200-days by -82.91% in comparison to the 20-day moving average, which settled at $1.0795. In addition, BioVie Inc saw -58.00% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BIVI
The total capital return value is set at -0.99. Equity return is now at value -154.54, with -102.89 for asset returns.
Based on BioVie Inc (BIVI), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -57.65. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -17.21.
Currently, EBITDA for the company is -31.95 million with net debt to EBITDA at 1.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.94.
Conclusion
To put it simply, BioVie Inc (BIVI) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
